![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EP400 |
Gene summary for EP400 |
![]() |
Gene information | Species | Human | Gene symbol | EP400 | Gene ID | 57634 |
Gene name | E1A binding protein p400 | |
Gene Alias | CAGH32 | |
Cytomap | 12q24.33 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96L91 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57634 | EP400 | LZE4T | Human | Esophagus | ESCC | 1.73e-10 | 2.20e-01 | 0.0811 |
57634 | EP400 | LZE7T | Human | Esophagus | ESCC | 6.05e-14 | 6.31e-01 | 0.0667 |
57634 | EP400 | LZE20T | Human | Esophagus | ESCC | 8.42e-09 | 1.56e-01 | 0.0662 |
57634 | EP400 | LZE24T | Human | Esophagus | ESCC | 4.95e-18 | 3.68e-01 | 0.0596 |
57634 | EP400 | LZE21T | Human | Esophagus | ESCC | 4.46e-09 | 3.24e-01 | 0.0655 |
57634 | EP400 | P1T-E | Human | Esophagus | ESCC | 2.28e-14 | 4.22e-01 | 0.0875 |
57634 | EP400 | P2T-E | Human | Esophagus | ESCC | 1.38e-47 | 8.30e-01 | 0.1177 |
57634 | EP400 | P4T-E | Human | Esophagus | ESCC | 7.30e-19 | 2.81e-01 | 0.1323 |
57634 | EP400 | P5T-E | Human | Esophagus | ESCC | 7.78e-14 | 2.20e-01 | 0.1327 |
57634 | EP400 | P8T-E | Human | Esophagus | ESCC | 1.18e-21 | 3.74e-01 | 0.0889 |
57634 | EP400 | P9T-E | Human | Esophagus | ESCC | 1.30e-15 | 1.80e-01 | 0.1131 |
57634 | EP400 | P10T-E | Human | Esophagus | ESCC | 1.66e-20 | 3.09e-01 | 0.116 |
57634 | EP400 | P11T-E | Human | Esophagus | ESCC | 1.75e-16 | 6.11e-01 | 0.1426 |
57634 | EP400 | P12T-E | Human | Esophagus | ESCC | 1.47e-14 | 2.28e-01 | 0.1122 |
57634 | EP400 | P15T-E | Human | Esophagus | ESCC | 2.57e-20 | 3.88e-01 | 0.1149 |
57634 | EP400 | P16T-E | Human | Esophagus | ESCC | 1.91e-23 | 3.72e-01 | 0.1153 |
57634 | EP400 | P17T-E | Human | Esophagus | ESCC | 1.52e-10 | 2.28e-01 | 0.1278 |
57634 | EP400 | P20T-E | Human | Esophagus | ESCC | 1.80e-23 | 4.72e-01 | 0.1124 |
57634 | EP400 | P21T-E | Human | Esophagus | ESCC | 1.99e-21 | 3.80e-01 | 0.1617 |
57634 | EP400 | P22T-E | Human | Esophagus | ESCC | 8.98e-12 | 2.46e-01 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
GO:00183944 | Oral cavity | OSCC | peptidyl-lysine acetylation | 108/7305 | 169/18723 | 4.55e-11 | 1.45e-09 | 108 |
GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
GO:00165734 | Oral cavity | OSCC | histone acetylation | 96/7305 | 152/18723 | 1.35e-09 | 3.29e-08 | 96 |
GO:00183934 | Oral cavity | OSCC | internal peptidyl-lysine acetylation | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
GO:00064754 | Oral cavity | OSCC | internal protein amino acid acetylation | 100/7305 | 160/18723 | 1.43e-09 | 3.41e-08 | 100 |
GO:00439674 | Oral cavity | OSCC | histone H4 acetylation | 49/7305 | 67/18723 | 1.45e-08 | 2.91e-07 | 49 |
GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
GO:00183947 | Thyroid | PTC | peptidyl-lysine acetylation | 99/5968 | 169/18723 | 6.54e-13 | 3.08e-11 | 99 |
GO:00064757 | Thyroid | PTC | internal protein amino acid acetylation | 92/5968 | 160/18723 | 1.80e-11 | 7.06e-10 | 92 |
GO:00183937 | Thyroid | PTC | internal peptidyl-lysine acetylation | 91/5968 | 158/18723 | 2.04e-11 | 7.91e-10 | 91 |
GO:00165737 | Thyroid | PTC | histone acetylation | 88/5968 | 152/18723 | 2.97e-11 | 1.10e-09 | 88 |
GO:00439677 | Thyroid | PTC | histone H4 acetylation | 45/5968 | 67/18723 | 3.16e-09 | 8.63e-08 | 45 |
GO:00439684 | Thyroid | PTC | histone H2A acetylation | 14/5968 | 17/18723 | 2.62e-05 | 2.56e-04 | 14 |
GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP400 | SNV | Missense_Mutation | c.5956G>C | p.Val1986Leu | p.V1986L | Q96L91 | protein_coding | deleterious(0.02) | possibly_damaging(0.826) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
EP400 | SNV | Missense_Mutation | c.1772A>G | p.Gln591Arg | p.Q591R | Q96L91 | protein_coding | deleterious_low_confidence(0.05) | benign(0.3) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
EP400 | SNV | Missense_Mutation | c.3646N>T | p.His1216Tyr | p.H1216Y | Q96L91 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-B6-A0RO-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
EP400 | SNV | Missense_Mutation | c.1907C>G | p.Ser636Cys | p.S636C | Q96L91 | protein_coding | deleterious_low_confidence(0.05) | benign(0.003) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
EP400 | SNV | Missense_Mutation | c.5629N>A | p.Glu1877Lys | p.E1877K | Q96L91 | protein_coding | tolerated(0.06) | possibly_damaging(0.84) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
EP400 | SNV | Missense_Mutation | c.5772C>A | p.Phe1924Leu | p.F1924L | Q96L91 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EP400 | SNV | Missense_Mutation | rs761256166 | c.1675G>A | p.Gly559Arg | p.G559R | Q96L91 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.64) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
EP400 | SNV | Missense_Mutation | c.3036N>A | p.Asn1012Lys | p.N1012K | Q96L91 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
EP400 | SNV | Missense_Mutation | rs753667262 | c.7931C>T | p.Pro2644Leu | p.P2644L | Q96L91 | protein_coding | tolerated_low_confidence(0.11) | benign(0.041) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP400 | SNV | Missense_Mutation | rs200268785 | c.2494N>T | p.Arg832Trp | p.R832W | Q96L91 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |